Success in the Commercialization of Academic Life Science Discoveries in Poland – A Case Study from Jagiellonian University

Radosław       Rudź

doi:10.2174/2213809907999200409093518

Abstract

Jagiellonian University (JU) is one of the top universities in Central and Eastern Europe. Several faculties of the university are conducting research in the life sciences area. These projects include both direct drug discovery and development activities as well as research aimed at the creation of novel technologies with significant commercial potential. The present case study is based on a series of examples illustrating the cooperation between JU and various business entities, both in Poland and globally, which successfully implemented the inventions made at the university. These cases include JU technologies already commercialized and also some of the most promising inventions still awaiting further development in close collaboration with various business partners. The article also describes a few examples of JU world-class research centres and their unique collaboration opportunities with scientific and business entities.

Keywords: Research commercialization, drug development, medical diagnostics, medical devices, technology portfolio, contract research.

« Previous Next »

[1] 
Ranking and web of universitied Europe 2019.[Accessed: March 3, 2020]. Available from:. https://www.webometrics.info/en/Ranking_Europe/Central_Eastern_Europe
[2] 
Krasowska M. Three universities from CEE rank in the Top 500 of the Shanghai Ranking 2018.[Accessed February 27, 2020]. Available from:. http://www.innovatecee.com/ecosystem/three-universities-from-cee-rank-in-the-top-500-of-the-shanghai-ranking/
[3] 
Reuters Top 100: Europe’s most innovative universities 2019 announced  [Accessed February 27, 2020]. Available from:. https://www.reuters.com/ article/rpbtop1002019/reuters-top-100-europes-most-innovative-universities-2019-announced-idUSKCN1S60PA
[4] 
Virtual clinical trials technology developed at the Jagiellonian University Science in Poland  [Accessed March 3, 2020]. Available from:. http:// scienceinpoland.pap.pl/en/news/news%2C394830%2Cvirtual-clinical-trials-technology-developed-at-the-jagiellonian-university.html
[5] 
Addressing drug candidates’ cardiotoxicity risk  [Accessed March 3, 2020]. Available from:. https://www.certara.com/wp-content/uploads/Resources/Brochures/BR_CardiacSafetySimulator.pdf
[6] 
Polak S, Wisniowska B, Fijorek K, Glinka A, Polak M, Mendyk A. ToxComp∔ in vivo in vitro extrapolation system for drug proarrhythmic potency assessment. Computing in Cardiol (CinC)  2012; 2012: 789-92.
[7] 
Shih HP, Zhang X, Aronov AM. Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications. Nat Rev Drug Discov  2018; 17: 19-33.
[8] 
Nanocapsule for delivery of lipophilic compound and process of preparation thereof [Accessed March 5, 2020]. Available from:. https://patentscope.wipo.int/ search/en/detail.jsf? docId=WO2017014655
[9] 
IntoDNA: where DNA breaks, our insights begins Available from:. www.intodna.com
[10] 
Kordon MM, Zarębski M, Solarczyk K, Ma H, Pederson T, Dobrucki JW. STRIDE-a fluorescence method for direct, specific in situ detection of individual single- or double-strand DNA breaks in fixed cells. Nucleic Acids Res  2020; 48(3) e14
[11] 
Innovative medical device for non-invasive evaluation of microcirculation and metabolic regulation using FMSF (Flow Mediated Skin Fluorescence) Available from:. https://angionica.com.pl/index_en.php
[12] 
Katarzynska J, Borkowska A, Los A, Marcinek A, Cypryk K, Gebicki J. Flow-mediated skin fluorescence (FMSF) technique for studying vascular complications in type 2 diabetes. Microvasc Res  2019; 124: 19-24.
[13] 
CERN courier J-PET’s plastic revolution [Accessed February 27, 2020]. Available from:. https:// cerncourier.com/a/j-pets-plastic-revolution/
[14] 
Malay AD, Miyazaki N, Biela A, et al. An ultra-stable gold-coordinated protein cage displaying reversible assembly. Nature  2019; 569(7756): 438-42.
[15] 
Grychowska K, Chaumont-Dubel S1, Kurczab R, et al. Dual 5-HT6 and D3 receptor antagonists in a group of 1H-Pyrrolo[3,2-c] quinolones with neuroprotective and procognitive activity. ACS Chem Neurosci  2019; 10(7): 3183-96.
[16] 
Zajdel P, Kos T, Marciniec K, et al. Novel multi-target azinesulfonamides of cyclic amine derivatives as potential antipsychotics with pro-social and pro-cognitive effects. Eur J Med Chem  2018; 145: 790-804.
[17] 
Marcinkowska M, Bucki A, Panek D, et al. Anti-alzheimer’s multi target-directed ligands with serotonin 5-HT6 antagonist, butyrylcholinesterase inhibitory and antioxidant activity. Archiv der Pharmazie  2019; 352(7): 1-10.
[18] 
Kaminski K, Socala K, Zagaja M, et al. N-Benzyl-(2,5-dioxopyrrolidin-1-yl)propanamide (AS-1) with hybrid structure as a candidate for a broad-spectrum antiepileptic drug. Neurotherapeutics  2020; 17(1): 309-28.
[19] 
Ciculate; about project Available from:. http://www.circulate.cm-uj.krakow.pl/
[20] 
Wojakowski W, Jadczyk T, Michalewska-Włudarczyk A, et al. Effects of transendocardial delivery of bone marrow-derived CD133+ cells on left ventricle perfusion and function in patients with refractory angina: final results of randomized, double-blinded, placebo-controlled REGENT-VSEL trial. Circ Res  2017; 120(4): 670-80.
[21] 
A composition for the treatment of human melanoma [Accessed March 5, 2020]. Available from:. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018135959&_cid=P12-K7EV77-98442-1.
[22] 
A middle ear prosthesis  [Accessed March 5, 2020]. Available from:. https://patentscope.wipo.int/ search/en/detail.jsf?docId=WO2018182439

Rights & Permissions Print Cite

Article Metrics

3

DOI https://dx.doi.org/10.2174/2213809907999200409093518	Print ISSN 2213-8099
Publisher Name Bentham Science Publisher	Online ISSN 2213-8102

Technology Transfer and Entrepreneurship (Discontinued)

Success in the Commercialization of Academic Life Science Discoveries in Poland – A Case Study from Jagiellonian University

Abstract Play Pause

Abstract